Amryt
Financials
Estimates*
USD | 2017 | 2018 | 2019 | 2020 | 2021 |
---|---|---|---|---|---|
Revenues | 15.3m | 17.1m | 58.1m | 183m | 223m |
% growth | - | 12 % | 240 % | 214 % | 22 % |
EBITDA | (30.0m) | (28.5m) | (42.7m) | (39.1m) | 67.6m |
% EBITDA margin | (196 %) | (167 %) | (74 %) | (21 %) | 30 % |
Profit | (31.4m) | (30.5m) | (63.0m) | (105m) | 1.0m |
% profit margin | (205 %) | (178 %) | (108 %) | (57 %) | - |
R&D budget | 12.7m | 10.7m | 15.8m | 27.6m | 37.7m |
R&D % of revenue | 83 % | 63 % | 27 % | 15 % | 17 % |
Date | Investors | Amount | Round |
---|---|---|---|
$9.0m | Late VC | ||
N/A | N/A | IPO | |
N/A | €2.0m | Post IPO Equity | |
N/A | €20.0m | Post IPO Debt | |
N/A | €33.0m Valuation: €350m 6.6x EV/LTM Revenues -9.0x EV/LTM EBITDA | Private Placement VC | |
* | $125m | Post IPO Debt | |
* | $1.3b Valuation: $1.3b | Acquisition | |
Total Funding | AUD70.0m |
Related Content
Recent News about Amryt
EditAmryt Pharma Plc is a commercial-stage pharmaceutical company dedicated to developing and delivering innovative treatments for rare and orphan diseases. The company focuses on providing solutions that significantly improve the lives of patients who suffer from these challenging conditions. Amryt Pharma operates in the global pharmaceutical market, serving healthcare professionals who treat complex and rare diseases. The business model is centered around the research, development, and commercialization of novel therapies. Revenue is generated through the sale of these specialized medicines and through strategic partnerships with other pharmaceutical companies. Amryt Pharma prides itself on its nimble and creative approach to business development, ensuring mutual benefits in all partnerships.
Keywords: rare diseases, orphan diseases, pharmaceutical, innovative treatments, healthcare professionals, global market, business development, strategic partnerships, commercialization, novel therapies.